Prognostic value of albumin-to-globulin ratio in COVID-19 patients: A systematic review and meta-analysis

Ulloque-Badaracco, Juan R.; Mosquera-Rojas, Melany D.; Hernández-Bustamante, Enrique A.; Alarcón-Braga, Esteban A.; Herrera-Añazco, Percy; Benítes-Zapata, Vicente A.

doi:10.1016/j.heliyon.2022.e09457

Cited by 12 publications

(9 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 68 Likewise, COVID-19 has been associated with a dysregulated immune response with lymphopenia, which is secondary to the migration and sequestration of T lymphocytes in organs infected by SARS-CoV-2, mainly the lungs, and overactivation with subsequent depletion of T cells. 69 – 71 Both patients with mucormycosis with or without COVID-19 showed elevated activation and exhaustion of T lymphocytes. However, patients with non-COVID-19 mucormycosis showed greater exhaustion of CD4 HLADR, CD38, and LAG-3 T lymphocytes, which could explain the worse prognosis in this group of patients.…”

Section: Discussionmentioning

confidence: 99%

Fungal infections in patients after recovering from COVID-19: a systematic review

Ulloque-Badaracco,

Copaja-Corzo,

Hernandez-Bustamante

et al. 2024

Therapeutic Advances in Infection

Self Cite

View full text Add to dashboard Cite

Background and aims: The presence of fungal infections has been described in patients after recovering from COVID-19. This study aims to conduct a systematic review of studies that reported fungal infections ( Mucor spp., Pneumocystis jirovecii, or Aspergillus spp.) in adults after recovering from COVID-19. Methods: We performed a systematic review through PubMed, Web of Science, OVID-Medline, Embase, and Scopus. The study selection process was performed independently and by at least two authors. We performed a risk of bias assessment using the Newcastle–Ottawa Scale for cohort and case–control studies, and the Joanna Briggs Institute’s Checklists for Case Series and Case Reports. Results: The systematic search found 33 studies meeting all inclusion criteria. There was a total population of 774 participants, ranging from 21 to 87 years. From them, 746 developed a fungal infection. In 19 studies, Mucor spp. was reported as the main mycosis. In 10 studies, P. jirovecii was reported as the main mycosis. In seven studies, Aspergillus spp. was reported as the main mycosis. Regarding the quality assessment, 12 studies were classified as low risk of bias and the remaining studies as high risk of bias. Conclusion: Patients’ clinical presentation and prognosis after recovering from COVID-19 with fungal infection differ from those reported patients with acute COVID-19 infection and those without COVID-19 infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Fungal infections in patients after recovering from COVID-19: a systematic review

Ulloque-Badaracco,

Copaja-Corzo,

Hernandez-Bustamante

et al. 2024

Therapeutic Advances in Infection

Self Cite

View full text Add to dashboard Cite

show abstract

“…The monocyte levels were decreased from baseline to the end of the Vasa treatment. A meta-analysis by Ulloque-Badaracco et al reported that a total of 11,356 patients from 31 cohort studies had lower AGR in severe COVID-19 and non-survivors than non-severe COVID-19 patients [ 45 , 46 ]. Our clinical trial findings also suggest that Vasa and combination of Vasa and Guduchi treated groups showed an increase in AG ratio and subsequently decreased Globulin levels.…”

Section: Discussionmentioning

confidence: 99%

Adhatoda vasica and Tinospora cordifolia extracts ameliorate clinical and molecular markers in mild COVID-19 patients: a randomized open-label three-armed study

Verma,

Rawat,

Rani

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Background SARS-CoV-2 infections caused mild-to-moderate illness. However, a sizable portion of infected people experience a rapid progression of hyper-inflammatory and hypoxic respiratory illness that necessitates an effective and safer remedy to combat COVID-19. Methods A total of 150 COVID-19-positive patients with no to mild symptoms, between the age groups 19–65 years were enrolled in this randomized, open-labeled three-armed clinical trial. Among them, 136 patients completed the study with RT-PCR negative reports. The patients received herbal drugs orally (Group A (Adhatoda vasica; AV; 500 mg; n = 50); Group B (Tinospora cordifolia; TC; 500 mg; n = 43), and Group C (AV + TC; 250 mg each; n = 43)) for 14 days. Clinical symptoms, vital parameters, and viral clearance were taken as primary outcomes, and biochemical, hematological parameters, cytokines, and biomarkers were evaluated at three time points as secondary outcomes. Results We found that the mean viral clearance time was 13.92 days (95% confidence interval [CI] 12.85–14.99) in Group A, 13.44 days (95% confidence interval [CI] 12.14–14.74) in Group B, and 11.86 days (95% confidence interval [CI] 10.62–13.11) days in Group C. Over a period of 14 days, the mean temperature in Groups A, and B significantly decreased linearly. In Group A, during the trial period, eosinophils, and PT/INR increased significantly, while monocytes, SGOT, globulin, serum ferritin, and HIF-1α, a marker of hypoxia reduced significantly. On the other hand, in Group B hsCRP decreased at mid-treatment. Eosinophil levels increased in Group C during the treatment, while MCP-3 levels were significantly reduced. Conclusions All the patients of the three-armed interventions recovered from COVID-19 and none of them reported any adverse effects from the drugs. Group C patients (AV + TC) resulted in a quicker viral clearance as compared to the other two groups. We provide the first clinical report of AV herbal extract acting as a modifier of HIF-1α in COVID-19 patients along with a reduction in levels of ferritin, VEGF, and PT/INR as the markers of hypoxia, inflammation, and thrombosis highlighting the potential use in progression stages, whereas the TC group showed immunomodulatory effects. Trial registration Clinical Trials Database -India (ICMR-NIMS), CTRI/2020/09/028043. Registered 24th September 2020, https://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=47443&EncHid=&modid=&compid=%27,%2747443det%27 Graphical Abstract

show abstract

“…Overall, these data seem to indicate that those patients with better protein nutrition will present a better response to rehabilitation treatment, as described [ 41 ]. Moreover, some studies [ 42 , 43 ] have linked higher albumin levels and lower globulin levels with a favorable prognosis for COVID-19. Further studies should validate this observation.…”

Section: Discussionmentioning

confidence: 99%

Clinical and Biomarker Profile Responses to Rehabilitation Treatment in Patients with Long COVID Characterized by Chronic Fatigue

Binetti

Real

Renzulli

et al. 2023

Viruses

View full text Add to dashboard Cite

Long COVID (LC) syndrome is a complex multiorgan symptom that persists beyond >12 weeks after SARS-CoV-2 infection. The most frequently associated symptom is fatigue. Physical activity and exercise are recommended, although specific studies are lacking. The objectives of the present work are to analyze the impact of a supervised exercise program on the clinical evolution of LC with fatigue patients and to identify whether certain circulating biomarkers could predict the response to rehabilitation. The rehabilitation treatment response was analyzed in 14 women diagnosed with LC and fatigue, based on the changes in the 6 min walk test and Borg/Fatigue Impact scales. Patients who showed improvement in the meters walked were considered “responders” to the therapy. A total of 65% of patients responded to the exercise program, with an improvement in the meters walked and in oxygen saturation, with stability in the percentage of meters walked. Participants with obesity and those double-vaccinated against SARS-CoV-2 presented a lower degree of fatigue. LC patients presented a favorable response to a supervised exercise program. Differences in creatinine and protein levels were observed between rehabilitation therapy “responders” and “nonresponders”. A good state of protein nutrition was related to a better rehabilitation response. The results are promising regarding possible predictive biomarkers of rehabilitation response, such as creatinine.

show abstract

Prognostic value of albumin-to-globulin ratio in COVID-19 patients: A systematic review and meta-analysis

Cited by 12 publications

References 65 publications

Fungal infections in patients after recovering from COVID-19: a systematic review

Fungal infections in patients after recovering from COVID-19: a systematic review

Adhatoda vasica and Tinospora cordifolia extracts ameliorate clinical and molecular markers in mild COVID-19 patients: a randomized open-label three-armed study

Clinical and Biomarker Profile Responses to Rehabilitation Treatment in Patients with Long COVID Characterized by Chronic Fatigue

Contact Info

Product

Resources

About